Dexamethasone palmitate is a feasible option for the treatment of chronic graft-vs-host disease, particularly with macrophage hyperactivation

Pediatr Transplant. 2020 Feb;24(1):e13627. doi: 10.1111/petr.13627. Epub 2019 Dec 11.

Authors

Yoshinaga Kurosawa¹, Daisuke Morita^{1

2}, Takumi Shibazaki¹, Kazutoshi Komori¹, Mitsuo Motobayashi¹, Tomonari Shigemura¹, Miyuki Tanaka¹, Yozo Nakazawa¹

Affiliations

¹ Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
² Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan.

PMID: 31828917
DOI: 10.1111/petr.13627

No abstract available

Keywords: chronic graft-vs-host disease; dexamethasone palmitate; liposteroid; macrophage hyperactivation; serositis.

Publication types

Case Reports
Letter

MeSH terms

Chronic Disease
Dexamethasone / therapeutic use*
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / immunology
Humans
Immunosuppressive Agents / therapeutic use*
Macrophages / immunology
Male
Palmitates / therapeutic use*
Young Adult

Substances

Immunosuppressive Agents
Palmitates
Dexamethasone